Results 71 to 80 of about 8,420 (193)

Ultrasmall Au10–12 Nanoclusters: A Novel Platform for 223Ra‐Targeted Tumor α‐Therapy

Exploration, Volume 6, Issue 2, April 2026.
Encapsulating 223Ra in Au10‐12 nanoclusters and functionalizing them with RGD peptides enables targeted α‐therapy and immune microenvironment remodeling in non‐osseous tumors like triple‐negative breast cancer. This study establishes a foundational framework for novel 223Ra‐labeled α‐radiopharmaceuticals and shows strong potential for clinical ...
Yifei Jiang, Huizhen Yang, Guoping Jia, Wangxi Hai, Rongyi Huang, Peng Wang, Min Zhang, Danni Li, Yizhou Chen, Xiao Li, Biao Li, Chunfu Zhang   +11 more
wiley   +1 more source

Additional file 1 of Automated synthesis of [89Zr]ZrCl4, [89Zr]ZrDFOSquaramide-bisPh(PSMA) and [89Zr]ZrDFOSquaramide-TATE

Additional file 1. Tables S1–S3; Synthesis S1 and S2; Figures S1–S4.
Noor, Asif, Roselt, Peter D., McGowan, Emily R., Poniger, Stan, Wheatcroft, Michael P., Donnelly, Paul S.   +5 more
openaire   +1 more source

Glypican-3 targeted positron emission tomography detects sub-centimeter tumors in a xenograft model of hepatocellular carcinoma

EJNMMI Research, 2023
Background Early intrahepatic recurrence is common after surgical resection of hepatocellular carcinoma (HCC) and leads to increased morbidity and mortality.
Kevin P. Labadie, Adrienne L. Lehnert, Aimee L. Kenoyer, Donald K. Hamlin, Andrew D. Ludwig, Alan F. Utria, Sara K. Daniel, Tara N. Mihailovic, Alexander Prossnitz, Johnnie J. Orozco, Yawen Li, D. Scott Wilbur, Robert S. Miyaoka, James O. Park   +13 more
doaj   +1 more source

Discovery of Yttrium, Zirconium, Niobium, Technetium, and Ruthenium Isotopes

, 2011
Currently, thirty-four yttrium, thirty-five zirconium, thirty-four niobium, thirty-five technetium, and thirty-eight ruthenium isotopes have been observed and the discovery of these isotopes is discussed here.
A. Nystrom, Ahrens, Antman, Arlt, Arlt, Asghar, Aston, Aston, Aston, Aston, Aston, Aston, Aten, Audi, Baró, Berg, Bernas, Bernas, Bohr, Born, Boyd, Boyd, Brady, Burgus, Butement, Butement, Cacciapuoti, Caretto Jr., Cheifetz, Clarke, De Jesus, De Vries, Della Negra, Delsasso, Deprun, Diamond, Doron, Doron, Dostrovsky, Downing, Dubridge, Duffield, Edwards, Eggen, Eidens, Ewald, Flegenheimer, Flegenheimer, Flegenheimer, Flegenheimer, Flegenheimer, Franz, Fritze, Ginepro, Glendenin, Glendenin, Goriely, Graefenstedt, Grawe, Griffiths, Grosse, Grummitt, Grummitt, Grüter, Gugelot, Gugelot, Gujrathi, Gunther, Götte, Hagberg, Hahn, Hahn, Hahn, Hahn, Hahn, Hahn, Hayden, Heiguchi, Helmholz, Hencheck, Hollander, Hopkins, Hopkins, Hotchkis, Huang, Hyde, Hübenthal, Hübenthal, Iafigliola, Jacobson, Janas, John, Kaba, Katcoff, Katcoff, Katcoff, Kienle, Knight, Korschinek, Korteling, Kundu, Kundu, Kuroyanagi, Lederer, Lederer, Leino, Liang, Lieber, Lister, Lister, Livingood, Livingood, Löbner, M. Thoennessen, Maurer, Maxia, Motta, Motta, Motta, Mukai, Nieckarz, Nishina, Ohnishi, Orth, Pecher, Penttilä, Perrier, Perrier, Pfeiffer, Pool, Riccato, Richardson, Robertson, Rudolph, Rykaczewski, Sagane, Sagane, Sagane, Seaborg, Seaborg, Seaborg, Seelmann–Eggebert, Segre, Selikson, Shizuma, Shizuma, Steinberg, Stewart, Stewart, Strominger, Sullivan, Takahashi, Thoennessen, Trautmann, Trautmann, Troutner, Vallis, Van der Wiel, Van Lieshout, Von Baeckmann, Votsilka, Watson, Wiles, Wohn, Yennello, Yu, Zaitseva, Zhou, Zingales, Äystö, Äystö   +170 more
core   +1 more source

Antibody–Drug Conjugates in Oncology: Principles, Clinical Development, and Future Directions

MedComm, Volume 7, Issue 4, April 2026.
Antibody–drug conjugates integrate antibody targeting with potent cytotoxic payloads to enable precision cancer therapy. Their clinical performance depends on coordinated optimization of engineering design, tumor antigen biology, and treatment strategy. Lessons from uro‐oncological malignancies illustrate how ADCs can be effectively developed, combined,
Bisheng Cheng, Lanqi Gong, Zongwei Wang, Peidan Peng, Kewei Xu, Hai Huang, Peng Wu   +6 more
wiley   +1 more source

Engineered CAR‐NKT Extracellular Vesicles Suppress Tumor Progression and Enhance Antitumor Immunity

Advanced Science, Volume 13, Issue 13, 3 March 2026.
TM4SF1‐nanobody engineered CAR‐natural killer T–derived extracellular vesicles (CARTM4SF1‐EVs) provide a cell‐free alternative to CAR‐NKT therapy, achieving potent, targeted antitumor activity with reduced toxicity. CARTM4SF1‐EVs induce immunogenic cell death, remodel the tumor microenvironment, and enhance CD8⁺ T‐cell antitumor immunity.
Xiaopei Hao, Chengming Qu, Yanzhao Zhou, Xiaoqian Wang, Xiangjun Qian, Xun Chen, Feng Han, Xiaokai Zhang, Yiyi Ji, Han Li, ChengWei Ju, Peng Xia, Weiwei Tang, Hao Zhuang, Jinxue Zhou   +14 more
wiley   +1 more source

89Zr anti-CD44 immuno-PET monitors  CD44 expression on splenic myeloid cells and HT29 colon cancer cells

Scientific Reports, 2021
CD44 is a cell-surface glycoprotein involved in cell–cell interaction, adhesion, and migration. CD44 is found on colon cancer cells and on immune cells.
Jin Won Park, Kyung-Ho Jung, Jin Hee Lee, Seung Hwan Moon, Young Seok Cho, Kyung-Han Lee   +5 more
doaj   +1 more source

Pushing indium phosphide quantum dot emission deeper into the near infrared [PDF]

, 2018
Cadmium-free near infrared (NIR) emitting quantum dots (QDs) have significant potential for multiplexed tissue-depth imaging applications in the first optical tissue window (i.e., 650 – 900 nm).
Dennis, A.M., Kays, Joshua, Mahler, Andrew, Saeboe, Alexander   +3 more
core   +1 more source

Companion Diagnostics in Clinical Therapy: Current Applications and Future Directions

MedComm, Volume 7, Issue 3, March 2026.
Companion diagnostics use biomarker‐based assays to stratify patients for precision therapies, improving outcomes while reducing ineffective treatment and side effects. This review summarizes the evolution, regulatory landscape, clinical applications, and technological platforms of CDx, highlighting their role in biomarker‐driven precision therapy.
Yuesong Wu, Rou Xue, Xiangwen Luo, Jiangnan Liao, Zongbo Zhang, Jinhai Deng, Teng Liu, Xin Li, Zhe‐Sheng Chen, Mingzhu Yin   +9 more
wiley   +1 more source

CD147/Basigin: From Integrative Molecular Hub to Translational Therapeutic Target

Advanced Science, Volume 13, Issue 8, 9 February 2026.
This review conceptualizes CD147 as a fundamental “Energy‐Structure Coupler,” physically bridging metabolic flux (via MCTs) with morphogenetic plasticity (via integrins/MMPs) to drive cancer, infection, and autoimmunity. Addressing the “specificity paradox” that limits current translation, the authors chart a strategic roadmap—spanning logic‐gated ...
Xiang‐Min Yang, Huijie Bian, Zhi‐Nan Chen   +2 more
wiley   +1 more source